Daily Stock Analysis, AST, Asterias Biotherapeutics Inc, priceseries

Asterias Biotherapeutics Inc. Daily Stock Analysis
Stock Information
Open
1.25
Close
1.25
High
1.30
Low
1.25
Previous Close
1.25
Daily Price Gain
0.00
YTD High
2.65
YTD High Date
Jan 12, 2018
YTD Low
1.25
YTD Low Date
Apr 24, 2018
YTD Price Change
-0.90
YTD Gain
-41.86%
52 Week High
4.30
52 Week High Date
Apr 26, 2017
52 Week Low
1.25
52 Week Low Date
Apr 24, 2018
52 Week Price Change
-2.50
52 Week Gain
-66.67%
Company Information
Stock Symbol
AST
Exchange
NYSE MKT
Company URL
http://www.asteriasbiotherapeutics.com
Company Phone
510-456-3805
CEO
Stephen Lahue Cartt
Headquarters
California
Business Address
6300 DUMBARTON CIRCLE, FREMONT, CA 94555
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001572552
About

Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. It also focus on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. The company was founded on September 24, 2012 and is headquartered in Menlo Park, CA.

Description

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company develops therapeutic products in the areas of neurology and oncology. Its clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke. The company also develops immunotherapeutic programs, such as AST-VAC1, an autologous product candidate that has completed a Phase II clinical trial for the treatment of acute myelogenous leukemia; and AST-VAC2, which is in a Phase I/IIa clinical trial, an allogeneic and cancer vaccine candidate designed to stimulate patient immune responses to telomerase. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.